A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

ASCVD - Atherosclerotic Cardiovascular Disease

CHD death-based MACE plus

3-point MACE, CV death-based MACE plus, Coronary heart disease death or MI, Cardiovascular death, All-cause death, Time to first event of MI, ischemic stroke, acute limb ischemia or major amputation, and urgent arterial revascularization, Percent change from baseline in LDL-C, Percent change from baseline in Apolipoprotein B, Percent change from baseline in Non-HDL-C, Percent change from baseline in Lipoprotein (a), Number of participants with an adverse event (AE), Number of participants discontinuing from study intervention due to AE

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Denmark